Eli Lilly's Elanco snags Novartis' animal health unit in $5.4B deal

When Novartis ($NVS) said it would take a hard look at its smaller business units, analysts quickly zeroed in on the Swiss drugmaker's animal health business. Too small to dominate in its market, the unit seemed ripe for divestment. Plus, it had some product-supply problems, thanks to manufacturing violations at a Nebraska plant. And the analysts were right: Novartis has agreed to sell its veterinary products business to Eli Lilly ($LLY), whose Elanco unit is among the biggest players in animal health, for about $5.4 billion. Release | Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.